Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion mentions Redensyl with 85% success rate and visible regrowth. Users skeptical, prefer Minoxidil, Finasteride, and RU58841.

Oral Minoxidil can cause puffy eyes and fluid retention. Adding an ACE inhibitor or ARB, like Telmisartan, may help mitigate these side effects.

The user experienced hair loss from age 16 to 24 and tried various treatments. Effective treatments included Finasteride, Minoxidil, and hair transplants, while thickening shampoos, biotin, laser hair therapy, and excessive exercise were ineffective.

Treatments for hair loss, such as topical minoxidil, platelet-rich plasma therapy with or without minoxidil, ketoconazole, non-abative radio frequency, natural products, finasteride and cortexolone 17 alpha propionate. The post evaluates the efficacy and safety of these treatments in various studies.

A user started using minoxidil and noticed a significant reduction in hair fall after two days. Other users expressed skepticism, suggesting that results typically take longer and may initially increase hair shedding.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

Quitting smoking may improve the effectiveness of finasteride and minoxidil for hair regrowth. Smoking is harmful to hair health, potentially increasing hair loss and reducing regrowth.

Minoxidil and finasteride topical solutions may last longer than their labeled best before date, with users experiencing varying side effects and effectiveness over time. Some users report reduced side effects and increased hair loss towards the end of the second month of use.

The user is using 0.5mg Dutasteride, 5mg oral Minoxidil, and topical Minoxidil daily for hair loss treatment. They report increased body hair and some improvement in hairline density and length.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

A 22-year-old male has been using oral minoxidil, oral finasteride, microneedling, and ketoconazole for hair loss treatment over two years, experiencing some regrowth and maintenance. He reports side effects from finasteride, including erectile dysfunction, and slight libido impact from minoxidil.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Finasteride and minoxidil stopped hair loss and improved urinary issues for a 34-year-old user. Despite some sexual side effects, the user plans to continue finasteride, while considering restarting minoxidil.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

A 25-year-old male using 1mg finasteride daily and 5% topical minoxidil twice daily noticed slight hair density improvement on the crown, less shedding, and no serious side effects except occasional mild discomfort. He uses Nizoral shampoo for itching and takes Vitamin D and Magnesium supplements, while maintaining a positive mental outlook and working on improving his sleep schedule.

A user shared their first-month progress using 0.25mg oral minoxidil and 0.5mg dutasteride daily for hair loss, noting some shedding and new hair growth without side effects. Another user mentioned experiencing intense shedding that decreased by week 6.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

Low-dose dutasteride (0.1 mg) is effective for hair growth, potentially more so than finasteride, with fewer side effects. East Asians may respond well to these treatments due to hair characteristics.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

Shampoos are not effective for stopping hair loss; treatments like minoxidil, finasteride, and dutasteride are more effective. Ketoconazole shampoo may help with scalp inflammation but not directly with hair loss.